Guidelines and Recommendations for Laboratory Analysis and Application of Pharmacogenetics to Clinical Practice

ABSTRACT (draft)

Objective: The objective of this LMPG on pharmacogenetics (PGx) is to provide a systematic rigorous assessment of the discipline of pharmacogenetics as it applies to clinical laboratory testing and its application to clinical practice. Issues to be addressed will be: methodological (pre-analytical and analytical) considerations, standardization and quality assurance of testing; selection of appropriate PGx testing profiles; recommended reporting of test results and interpretation; standards needed for demonstration of clinical utility and efficacy; and, recommendations for effective use of pharmacogenetic information in a clinical setting.

Background. Although still in its infancy, the availability and application of information derived from pharmacogenetic-related clinical laboratory tests has provided major inroads and expectations to the concept of personalized therapeutics. PGx as a clinical adjunct to selection and dosing of drugs is relatively new and as such, medical practitioners, clinical laboratories, in-vitro diagnostic manufacturers and regulators of diagnostic tests have not established evidence-based guidelines needed to optimize practice in their respective areas of application. These present Guidelines provide a framework on which to build a rigorous and systematic approach to establishing optimum use of pharmacogenetic-information obtained from clinical laboratory testing. The Guidelines also establish criteria and critical pathways that must be met before the efficacy of this testing can be rigorously assessed.

Approach: An expert committee is drafting evidence-based recommendations (where available) pertaining to the areas of focus. An external panel of experts will review a draft of the Guidelines which will be modified in response to reviewer’s suggestions. A revised draft will be posted on the internet and also presented for open comments at the IATDM/CT meeting in Louisville April 2005 (www.iatdmct.org and also see below) and at 2 other national open meetings (to be determined) before final presentations at the AACC 2006 Annual Meeting. Recommendations will again be modified after input from these activities and subsequently submitted for publication in CCJ (or /and other) by end of same.

Content: (Under development)

Summary: We recognize that this relatively new application derived from combining genetic–testing with traditional pharmacology is rapidly evolving and as such the guidelines are likely to also evolve rapidly. Nevertheless, these present guidelines will serve as a basis on which to establish a rigorous approach to defining the applications of this discipline to clinical practice and to define critical pathways and provide the laboratory support needed to bring this application to routine healthcare.
### Projected timeline for development of the pharmacogenetics LMPG

<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 2004</td>
<td>Organizing Cmte telecons to prepare structure, budget</td>
</tr>
<tr>
<td>June/July 2004</td>
<td>Seek financial support / NACB web posting to build LMPG (individual section outlines prepared, systematic reviews, etc.)</td>
</tr>
<tr>
<td>Aug / Sept 2004</td>
<td>Organizing Cmte meets physically to structure LMPG</td>
</tr>
<tr>
<td>Sept 2004</td>
<td>Selection of primary review group, approx 20-30 individuals</td>
</tr>
<tr>
<td>Jan 2005</td>
<td>First posting on NACB web page as announcement</td>
</tr>
<tr>
<td>Feb / Mar 2005</td>
<td>Prepared first draft for primary reviews and structure</td>
</tr>
<tr>
<td>April 2005</td>
<td>First consensus presentation at IATDM/CT, Louisville</td>
</tr>
<tr>
<td>June 2005</td>
<td>Submit draft for primary expert reviewers / comments compiled</td>
</tr>
<tr>
<td>August 2005</td>
<td>Near final document; start to present at several discipline-specific venues*</td>
</tr>
<tr>
<td>March 2006</td>
<td>Post again on NACB Web for additional comments</td>
</tr>
<tr>
<td>July 2006</td>
<td>Presentation of product at AACC Annual Meeting as Edutrack</td>
</tr>
</tbody>
</table>

* Please contact LMPG Chairperson if interested in having parts of this LMPG presented at your scientific or clinical venue.
NACB Laboratory Medicine Practice Guidelines on Applications of Pharmacogenetics Testing

First discussion to be presented at International Therapeutic Drug Monitoring and Clinical Toxicology (IATDM/CT) Congress in Louisville, Kentucky 2005 (April 27th and 28th)

Wednesday AM/PM and Thursday AM sessions

Objective is to establish practice guidelines for application of pharmacogenetics (PGx) in the practice of laboratory medicine.

These sessions will be used to develop an understanding of the present evidence supporting the application of pharmacogenetics-testing to general clinical practice and specific areas of medical practice. In these discussion sessions will:

1) Define what parameters are necessary to provide optimum pharmacogenetics-testing in specific clinical settings

2) Define the potential links in the roles of pharmacogenetics and therapeutic drug monitoring in clinical settings

3) Discuss and formulate recommended guidelines for clinical laboratories introducing Pharmacogenetics-testing services

4) Provide in-vitro diagnostic companies parameters necessary for optimizing clinical assays needed in pharmacogenetics-testing

5) Provide third party payers and regulators of diagnostic laboratory testing recommended parameters for optimizing their reimbursement and regulatory functions
Committee for the 2006 LMPG on Pharmacogenetics

Chairperson:
Roland Valdes, Jr., Ph.D., FACB
University of Louisville
Department of Pathology
and Laboratory Medicine
MDR Bldg. Suite 208
511 S. Floyd Street
Louisville, KY 40292
Phone: 502-852-1772
rvaldes@louisville.edu

Mark W. Linder, Ph.D., FACB
University of Louisville
Department of Pathology
and Laboratory Medicine
MDR Bldg. Suite 217
511 S. Floyd Street
Louisville, KY 40202
Phone: 502-852-8400
mwlind01@gwise.louisville.edu

Daniel H. Farkas, Ph.D., FACB
Baylor College of Medicine
Department of Pathology
The Methodist Hospital
6565 Fannin MS-205
Houston, TX 77030
Phone: 713-441-7103
dfarkas@bcm.tmc.edu

Howard McLeod, Ph.D.
Washington University
School of Medicine
660 S. Euclid Avenue
St. Louis, MO 63110-1010
Phone: 314-747-5183
hmcleod@im.wustl.edu

David A. Flockhart M.D., Ph.D.
Professor of Medicine, Medical Genetics,
and Pharmacology
Chief, Division of Clinical Pharmacology
Department of Medicine
1001 West 10th Street
WD Myers Bldg. - W7123
Indianapolis, IN 46202
Phone: 317-630-8795
dflockha@iupui.edu

Deborah Ann Payne, Ph.D.
The University of Texas Medical Branch
Department of Pathology
301 University Blvd.
Galveston, TX 77555-0743
Phone: 409-772-9129
dpayne@utmb.edu

Lawrence J. Lesko, Ph.D.
Food and Drug Administration
Director, Office of Clinical Pharmacology
and Biopharmaceutics
5600 Fisher Lane - MC HFD-850
Room 6A19
Rockville, MD 20857
Phone: 301-594-5690
leskol@cdr.fda.gov

Gualberto Ruano, M.D., Ph.D.
Genomas
P. O. Box 9595
New Haven, CT 06535
Phone: 203-687-0753
m.solomon@genomas.net

Leslie M. Shaw, Ph.D., FACB
Hospital of the University of Pennsylvania
Department of Pathology
and Laboratory Medicine
7.103 Founders Pavilion
3400 Spruce Street
Philadelphia, PA 19104
Phone: 215-662-6575
shawlmj@mail.med.upenn.edu